Abnormalities of striatal function have been implicated in several major neurological and psychiatric disorders, including Parkinson's disease, schizophrenia and depression. Adenosine, via activation of A 2A receptors, antagonizes dopamine signaling at D2 receptors and A 2A receptor antagonists have been tested as therapeutic agents for Parkinson's disease. We found a direct physical interaction between the G protein-coupled A 2A receptor (A 2A R) and the receptor tyrosine kinase fibroblast growth factor receptor (FGFR). Concomitant activation of these two classes of receptors, but not individual activation of either one alone, caused a robust activation of the MAPK/ERK pathway, differentiation and neurite extension of PC12 cells, spine morphogenesis in primary neuronal cultures, and cortico-striatal plasticity that was induced by a previously unknown A 2A R/FGFR-dependent mechanism. The discovery of a direct physical interaction between the A 2A and FGF receptors and the robust physiological consequences of this association shed light on the mechanism underlying FGF functions as a co-transmitter and open new avenues for therapeutic interventions.
The striatum, a component of the basal ganglia, receives dopaminergic innervation from the substantia nigra and glutamatergic innervation from the cortex. It moderates the control of complex motor activity and cognitive aspects of motor control. Medium spiny neurons, which represent over 90% of all striatal neurons, are the only known efferent neurons of the striatum. Roughly half of these neurons (the striatopallidal projection) contain A 2A Rs. A 2A Rs have an important role in the striatum through their coupling to G s /G olf proteins. Their signaling actions are opposed by those of D2 dopamine receptors, which are located on the same cells and are coupled to G i/o and G q proteins 1 . Striatal A 2A Rs are activated by adenosine that is generated by ecto-nucleotidase degradation of ATP released by neurons and astrocytes 2 . The stimulatory effects of caffeine on locomotor activity are attributable to blockade of A 2A Rs 3 . Conversely, A 2A R agonists inhibit movement 4 . Abnormalities in striatal A 2A R signaling have been implicated in Parkinson's disease, schizophrenia, attention deficit hyperactivity disorder and drug abuse (for a review, see ref. 5 ), leading to a concerted effort to develop pharmacological agents that act at these receptors. Thus, clarification of the signaltransduction mechanisms associated with A 2A Rs may help the design of improved therapeutic agents.
FGFs are polypeptides that signal through a family of four major receptors 6 . For a long time, FGFs were known to only have a trophic role in basic cells such as fibroblasts. Recently, FGFs have been shown to be important in neural induction, neural plate patterning, and neuronal proliferation and survival, as well as in presynaptic organization [7] [8] [9] [10] . Several recent studies have provided evidence that the expression of FGF is regulated in the brain by different stimuli, including dopamine, cocaine and stress 11, 12 . As with other growth factors, FGF has also been hypothesized to be important in the adult nervous system 6 . One of the functions of tyrosine kinaselinked receptors in the adult brain is to regulate the synaptic plasticity that is thought to underlie learning and memory. For example, BDNF is an important regulator of synaptic plasticity in the adult hippocampus. Both FGF and FGF receptors are abundantly expressed in the striatum 13 . Moreover, there is increasing evidence for a neuroprotective role for FGFs and FGFRs in the striatum, suggesting that this growth factor may affect synaptic plasticity in this brain region.
Here we present direct evidence that the FGF system is important in the modulation of synaptic plasticity, specifically in the corticostriato-pallidal pathway. We found that A 2A R-FGFR co-stimulation caused a marked synergistic increase in neurite formation and spine density, and induced a form of cortico-striatal long-term potentiation (LTP) in striatopallidal neurons. The mechanism underlying these phenomena appears to involve a direct physical interaction between the A 2A R and the FGFR. This interaction lead to the synergistic activation of MEK1/2 and consequently to a robust increase of ERK1/2 phosphorylation, which occurred rapidly and was long lasting. We propose a 'proximity model' to account for the synergistic interaction that we observed.
RESULTS

Identification of FGFR as an A 2A R-interacting protein
To search for previously unknown molecular mechanisms that might affect the actions of the dopamine modulator adenosine, we used the yeast two-hybrid method to identify proteins that could selectively bind to the A 2A R. We subcloned the cDNA corresponding to the last 133 amino acids of the intracellular C-terminal sequence of the A 2A R (residues 278-410) into a pAS2-GAL4-derived plasmid and used it as bait (A 2A R 278-410 ). We screened 25 Â 10 6 diploid clones from a pACT2 cDNA library. Out of more than 1,000 histidine-positive clones, 71 clones were also positive for the b-galactosidase reporter gene. To our surprise, we found that 7 of the 50 sequenced double-positive clones shared sequence similarities with the cytoplasmic tail of fibroblast growth factor receptor 1 (FGFR1). To determine the specificity of interaction, we amplified the FGFR prey plasmid corresponding to the smallest fragment of the FGFR (666-822) rescued from yeast in E. coli and transformed it into yeast that harbored the original A 2A R 278-410 bait plasmid, the empty bait plasmid (-) or one of four irrelevant baits (two viral proteins and two yeast proteins). The interaction was specific, as only the FGFR (666-822) and A 2A R (278-410) interaction was positive (Fig. 1a) .
To confirm the A 2A R-FGFR interaction, we employed a GST pulldown assay. Radiolabeled FGFR domain (666-822) or full length FGFR (FGFR.FL) was incubated with the same amount of either GSTor GST-A 2A R . GST-A 2A R 278-410 fusion protein, but not GSTalone, pulled down both FGFR 666-822 (data not shown) and FGFR.FL (Fig. 1b) as demonstrated by SDS-PAGE analysis. As a control, we found that GST-A 2A R 278-410 did not interact with radiolabeled luciferase (Fig. 1b) . To investigate the interaction between full-length A 2A R and native FGFR in mammalian cells, we expressed full-length hemagglutinin (HA)-tagged A 2A R in COS-7 cells. A 2A R-HA was immunoprecipitated using an antibody to HA, and bound FGFR was detected by immunoblotting with an antibody to FGFR. Endogenous FGFR was co-immunoprecipitated with A 2A R-HA (Fig. 1c) , whereas no FGFR was detected in immunoprecipitates in the absence of the antibody to HA (Fig. 1c) , and FGFR was coimmunoprecipitated from cells transfected with the empty plasmid (Fig. 1c) or from non-transfected cells (Fig. 1c) .
Characterization of the domains of interaction
We cloned fragments corresponding to different regions of A 2A R 278-410 and FGF 666-822 into the bait and prey plasmids, respectively. The constructs were transformed in yeast and their expression was confirmed by immunoblot using an antibody to Gal4. We found that amino acids 278-315 of A 2A R were sufficient for interaction with amino acids 666-822 of FGFR (Fig. 2a) . Conversely, amino acids 666-788 of FGFR were necessary for interaction with amino acids 278-410 of A 2A R (Fig. 2b) . Amino acids 666-788 of FGFR contain two tyrosine residues, Tyr730 and Tyr766, which are phosphorylation sites and are extremely well conserved among growth factor tyrosine kinase receptors. Phosphorylation on Tyr766 leads to activation of phospholipase Cg and is involved in the internalization of the FGFR1 (refs. 14,15), whereas the function of Tyr730 phosphorylation remains unclear. To test the possibility that one or both of the tyrosines are involved in the A 2A R/FGFR interaction, we made single alanine and aspartic acid mutants for each position. By GST pull-down, we found that mutant Y766D, but not Y766A, Y730D or Y730A, showed reduced binding to A 2A R 278-410 , indicating that phosphorylation at Tyr766 may negatively regulate the A 2A R/FGFR interaction ( Supplementary Fig. 1 online) .
We designed a synthetic peptide corresponding to the minimal region of interaction found for the A 2A R (amino acids 278-315). The resulting peptide effectively disrupted the pre-formed interaction in a GST pull-down assay experiment using a GST-A 2A R fusion protein and a radiolabeled in vitro-transcribed FGFR (Fig. 2c ).
CGS21680 and FGF synergistically activate the ERK pathway
Functional studies evaluating the physiological consequences of the interaction of the A 2A Rs and FGFRs initially used PC12 cells, a cell line that has been confirmed to express A 2A R and FGFR (data not shown) 16, 17 . After 48 h of serum starvation (0.5% fetal calf serum), we treated PC12 cells with the A 2A R agonist CGS21680 alone, aFGF alone or a combination of CGS21680 and acidic FGF (aFGF). As a biochemical readout of possible cross-talk between activation of A 2A Rs and FGFRs, we measured the phosphorylation of ERK1/2, a known downstream target of each receptor (Fig. 3a,b) . We did not observe a substantial increase in ERK1/2 phosphorylation with either CGS21680 alone (250 nM) or aFGF alone (5 ng ml -1 ) until after 30 min of incubation (Fig. 3a,b) . In contrast, at 10 min of incubation, the simultaneous addition of CGS21680 and aFGF resulted in a greater than 15-fold increase in ERK1/2 phosphorylation. Dose-response studies indicated that a combination of 1 mM CGS21680 and 20 ng ml -1 aFGF resulted in maximal synergistic phosphorylation of ERK1/2 ( Fig. 3c,d ). We confirmed the specificity for CGS21680 acting at A 2A Rs with ZM241385, a selective A 2A R antagonist, which induced a dose-dependent inhibition of the CGS21680/aFGF-dependent increase in ERK1/2 phosphorylation (Fig. 3e) . We have also found that the FGFR inhibitor PLX052 (PLX) abolished the synergistic effects that we observed in a concentration-dependent manner (Fig. 3f) . Finally, we found that a penetrating peptide corresponding to the minimal A 2A R domain of interaction (see Fig. 2 ) blocked the synergistic activation of ERK (Fig. 3g) . Stimulation with CGS21680 or aFGF alone in the same conditions led to only a weak stimulation of ERK phosphorylation and only at the highest doses (Fig. 3h) . We next investigated the signaling steps that might be subject to synergistic regulation by activation of A 2A Rs and FGFRs. By using various phospho-specific antibodies directed against c-Raf, MEK1/2 and ERK1/2, we found that MEK1/2 was the first protein of the MAP kinase cascade to become highly phosphorylated in a synergistic manner on simultaneous stimulation by aFGF and CGS21680 ( Supplementary Fig. 2 online) . No activation of the p38 MAPK or SAPK/JNK pathways was observed (data not shown). In addition, aFGF failed to alter CGS21680-induced cAMP formation and CGS21680 failed to affect FGF-induced phosphorylation of FGFR ( Supplementary Fig. 3 online) .
To further investigate the nature of the observed synergism, we tested the possibility that FGFR activation may affect A 2A R signaling indirectly by altering its cell surface expression or internalization. Our results could be explained by FGF increasing the cell surface expression of A 2A R. We incubated PC12 cells for either 10 or 60 min with CGS21680 (Fig. 4a) .
The two receptors (A 2A R and A 2A R-6-7TM) were similarly expressed in COS-7 cells (Fig. 4b) . We compared their capacity to be activated by CGS21680 by measuring cAMP production (Fig. 4c) . Wild-type A 2A R was active and positively coupled to adenylyl cyclase, as shown by cAMP production on CGS21680 stimulation. In contrast, the A 2A R-6-7TM mutant did not respond to CGS21680 with the production of cAMP, nor did it alter the response of wild-type A 2A R to CGS21680 (Fig. 4c) . However, expression of A 2A R-6-7TM resulted in a 52% reduction of the ERK1/2 phosphorylation that we observed in response to CGS21680/aFGF (Fig. 4d) . These results provide strong support for the conclusion that a direct physical interaction between the A 2A R and the FGFR is required for the synergistic activation of ERK1/2. TM1  TM7  TM6  TM5  TM4  TM3  TM2   N terminus  C terminus   TM1  TM5  TM4  TM3  TM2   60 Morphological consequences of the A 2A R/FGFR coactivation PC12 cells manifest certain morphological aspects of neuronal differentiation in the presence of growth factors such as FGF, as well as agents that stimulate cAMP levels. Moreover, activation of the MAP kinase pathway has been implicated in the differentiation of PC12 cells and in the elaboration of neurites 18 . We incubated PC12 cells with aFGF and/ or CGS21680 for 4 d (Fig. 5) . In the absence of ligand, PC12 cells were spherical (Fig. 5a ). After activation with CGS21680 or aFGF, cells began to differentiate and neurite extensions appeared. However, when both ligands were applied simultaneously, there was a marked increase in the number of cells with extensions and in the average number of extensions per cell (Fig. 5c,d) . Pre-incubation with the penetrating A 2A R inhibitory peptide (Pep, 50 mM) or the FGFR inhibitor PLX (10 mM) blocked the synergistic effects of CGS21680/aFGF on neurite extension (Fig. 5a,c,d ). PC12 cells that were co-stimulated with CGS21680/aFGF in presence of the A 2A R antagonist ZM241385 were similar to PC12 cells incubated with aFGF alone (data not shown).
The MAP kinase pathway has been implicated in various aspects of neuronal development and synaptic plasticity, including regulation of dendritic spine morphogenesis [19] [20] [21] . In view of the strong ERK activation that we have observed here, we investigated the possibility that the synergistic action observed between CGS21680 and aFGF could influence protrusion density in cultured hippocampal neurons. Neuronal cultures were incubated for 60 min in the absence or presence of CGS21680 and/or aFGF (representative segments of dendrites from neurons expressing CD8 as a volume marker are shown in Fig. 5b) . In control neurons, the protrusion density was 27.1 ± 3.2 per 100 mm. Treatment with CGS21680 alone, aFGF alone or CGS21680 and aFGF caused increases in mean density of protrusions per 100 mm of 4.8% ± 0.8, 12.2% ± 1.1 and 65% ± 1.7%, respectively, compared with paired untreated control cultures (Fig. 5b,e) . Treatment with the MEK inhibitor U0126, but not with an inactive analog U0124, inhibited the effect of co-application of CGS21680 and aFGF treatment by 83% (Fig. 5b,e) . Synergistic facilitation of corticostriatal LTP Given the ability of the A 2A R/FGFR interaction to synergistically activate ERK1/2 and to synergistically increase spine morphogenesis, we tested the possibility that combined activation of A 2A Rs and FGFRs might be involved in the regulation of corticostriatal synaptic plasticity (Fig. 6) . We studied plasticity at glutamatergic, corticostriatal synapses in parasagittal brain slices (Fig. 6a ) from BAC transgenic mice in which either D 1 receptor-expressing striatonigral medium spiny neurons (MSNs) or D 2 receptor-expressing striatopallidal MSNs were labeled with green fluorescent protein. As previously reported 22 , activation of A 2A Rs with the selective agonist CGS21680 (10 nM) had no effect on basal AMPA receptor-mediated corticostriatal synaptic transmission in either type of MSN (data not shown, n ¼ 2), and FGF (10 ng ml -1 ) did not affect basal synaptic transmission (data not shown, n ¼ 3). ERK1/2 activation has been implicated in forms of LTP induced by pairing high-frequency stimulation (HFS) of glutamatergic synapses with postsynaptic depolarization 23 .
In parasagittal brain slices that preserved the connectivity between the cerebral cortex and the striatum, pairing of corticostriatal HFS with depolarization of striatopallidal MSNs led to a modest LTP in about one-third of the neurons examined (26 ± 8% in 6 of 20 neurons). LTP was not observed in any of the striatonigral MSNs tested (n ¼ 5). Preincubation of slices with both A 2A R agonist CGS21680 (10 nM) and FGF (10 ng ml -1 ) markedly enhanced the induction of LTP by HFSdepolarization pairing in striatopallidal MSNs (n ¼ 11; Fig. 6b,c,h ), whereas it had no affect on LTP induction in striatonigral MSNs (n ¼ 5, data not shown). This form of LTP resembled that previously described in MSNs 24, 25 , as it was abolished by blockade of NMDA receptors with 2-amino-5-phosphonopentanoic acid (50 mM, n ¼ 3) and was reversed (depotentiated) by low-frequency (2 Hz) afferent stimulation (n ¼ 6; Fig. 6d ). Coactivation of A 2A R and FGFR was necessary for LTP induction, as exposure of slices to either the FGFR inhibitor PLX052 (10 mM; Fig. 6e,h) , the A 2A R antagonist SCH58261 (0.1 mM; Fig. 6f,h ) or the tyrosine kinase inhibitor SU5402 (10 mM; Fig. 6h ) abolished LTP induction.
Although coactivation of A 2A R and FGFR alone did not affect AMPA receptor-mediated synaptic transmission, it did substantially enhance NMDA receptor-mediated current in D2 MSNs ( Supplementary  Fig. 4 online) . In contrast with previous reports, the induction of LTP by pairing HFS-depolarization was unaffected by antagonizing D 1 dopamine receptors with SCH23390 (3 mM, n ¼ 8; Fig. 6g,h ). However, induction was blocked by the D 2 receptor agonist quinpirole (5 mM, n ¼ 5; Fig. 6g,h) , which is known to antagonize A 2A R signaling. Consistent with our biochemical analysis of the A 2A R/FGFR synergy, inhibition of MEK with U0126 (10 mM), but not with an inactive analog, U0124 (data not shown), completely prevented LTP induction (n ¼ 5; Fig. 6h ).
DISCUSSION
Numerous studies since the early 1970s have investigated the biological consequences of receptor oligomerization 26 . In the late 1980s, an allosteric receptor oligomerization model was proposed for the tyrosine kinase receptors 27 . In the 1990s, models proposing GPCR homodimers, as well as oligomers, appeared 28 . Gradually, the classical 1:1:1 stoichiometry models (one ligand, one receptor and one G protein) are being replaced by models involving higher-order complexes 29 . However, despite the growing number of publications relating to receptor dimerization (for reviews, see refs. 5, 30, 31) little is known about the structural basis of receptor-receptor interactions or about the functional consequences of oligomer formation. Our results strongly suggest that a direct physical interaction between the A 2A R and the FGFR is important for ERK-dependent regulation of morphological and physiological synaptic plasticity at striatopallidal synapses. Notably, the A 2A R is highly expressed in striatopallidal neurons, and FGF receptors are known to be expressed in medium spiny neurons 32 . What is the molecular basis by which the physical interaction of A 2A Rs and FGFRs produces the pronounced synergistic activation of the ERK/ MAP kinase pathway described here? The FGFR is coupled to the ERK/ MAPK pathway through a Grb2/Ras/Raf-cascade. The ERK/MAPK pathway can also be activated by the A 2A R via cAMP/PKA-EPAC/Rafdependent stimulation of MEK1/2. Our study argues against A 2A Rs increasing tyrosine phosphorylation of the FGFR and against activated FGFRs increasing cAMP levels or A 2A R localization on the cell surface.
We propose a 'physical proximity' model to explain the synergistic action resulting from co-stimulation of A 2A Rs and FGFRs. This model postulates that the physical interaction between A 2A Rs and FGFRs, by confining both receptors to the same microcellular environment, results in dual phosphorylation of a downstream signaling molecule. The ERK/MAPK pathway activation is believed to be entirely dependent on protein kinase phosphorylation events and the observed synergism is consistent with the fact that MEK activation requires phosphorylation on at least two serine residues in the activation loop. However, it is conceivable that protein phosphatases, by dephosphorylating inhibitory sites, could also be involved in activating a given signaling complex or keeping it in its optimal configuration. A recent study implicating a protein phosphatase cascade in the regulation of ERK in the striatum supports this possibility 33 . In summary, our model suggests that MEK/ERK activation occurring under conditions of relatively low receptor occupancy by adenosine and FGF would serve to markedly amplify the coincident activation of the ERK/MAPK pathway by A 2A Rs and FGFRs. On the basis of the high degree of identity (98%) between the tyrosine kinase domains of the various FGFR isoforms, it is possible that not only FGFR1, the one that we found here, but also FGFR2 and 3 may also be involved, as these isoforms are expressed in MSNs 32 .
Our studies revealed that coactivation of A 2A Rs and FGFRs, which results in stimulation of ERK1/2, was necessary for the induction of LTP by HFS-depolarization pairing at corticostriatal synapses of striatopallidal MSNs but not neighboring striatonigral MSNs. The induction of plasticity is probably a result of direct postsynaptic effects of FGF and A 2A receptors in striatopallidal MSNs for several reasons. Our reliance on parasagittal brain slices that preserve the connectivity between MSNs and cortical pyramidal neurons 34 allowed us to selectively activate corticostriatal axons during the induction protocol but not fibers passing through the striatum or the heterogeneous population of neurons intrinsic to the striatum. Although corticostriatal axons potently activate fast-spiking GABAergic interneurons 35 , blocking GABAergic receptors had no effect on the induction of LTP, indicating that they were not a factor in the induction of plasticity 36 . Cholinergic interneurons, which can promote the induction of LTP at MSN glutamatergic synapses 36 , are only weakly activated by cortical inputs; moreover, adenosine inhibits the opening of the voltage-dependent Ca 2+ channels that control the release of acetylcholine 37 , arguing against any role for these interneurons in our results. The restriction of the plasticity to corticostriatal synapses formed on striatopallidal MSNs is consistent with previous studies showing that A 2A R expression in the striatum is almost entirely limited to neurons that coexpress D2 dopamine receptors and the releasable peptide enkephalin [37] [38] [39] . The cellular specificity is also consistent with the observation that corticostriatal LTP, measured with field potential recording, is reduced, but not eliminated, by genetic deletion of A 2A Rs, as this approach will average changes in both striatonigral and striatopallidal MSNs.
In contrast with previous reports 40, 41 , however, the NMDA receptordependent LTP in striatopallidal MSNs did not require activation of D1 dopamine receptors. Because the D1 receptors are localized almost exclusively in striatonigral MSNs 42, 43 , this finding is understandable. Our results suggest that dopamine is a negative modulator of LTP induction in striatopallidal MSNs. This observation agrees with a variety of studies showing that D2 and A 2A receptors are capable of inhibiting one another 38, 39 and provides strong evidence that an interaction between A 2A R and FGFR is important for the regulation of synaptic plasticity in striatopallidal MSNs. The ability of D 2 receptors to disrupt LTP induction in striatopallidal MSNs and to promote the induction of LTD 25, 44 has fundamental implications for striatum-based models of reinforcement learning. We have focused our analysis on the role of the interaction of A 2A R and FGFR in synaptic plasticity of striatopallidal neurons, but our findings raise the possibility that this interaction might also be relevant to signaling in other neurons in the brain that coexpress the two proteins.
The demonstration of synergy between the A 2A R and FGFR pathways has major clinical implications. A 2A Rs, through their localization in striatopallidal neurons, are important for modulating the actions of dopamine acting at D2 receptors. Thus, signaling through the A 2A R pathway has become an increasingly attractive target for the development of therapeutic agents for Parkinson's disease and schizophrenia. In addition, a variety of growth factors and neurotrophic factors have been tested for clinical efficacy in several neurological and psychiatric disorders. For example, enhanced neuroprotective effects of injected basic FGF in regional brain ischemia were recently observed after conjugation to a blood-brain barrier delivery vector 45 . The discovery of cross-talk between the A 2A R and the FGFR provides a new range of possibilities for therapeutic interventions affecting both pathways.
METHODS
Yeast two-hybrid analysis. Yeast two-hybrid experiments were carried out as described previously 46 . Briefly, the yeast strain Y187 was transformed with bait and prey plasmids using the lithium acetate Tris EDTA protocol, and protein expression of the baits and preys was analyzed by immunoblotting using an antibody to the GAL4 binding domain.
Production of recombinant proteins. PCR fragments corresponding to the different proteins of interest were purified and digested by the appropriate restriction enzymes and then subcloned into the pGEX4T1 vector (Amersham Pharmacia Biotech). The resulting constructs were transformed into the bacterial host strain BL21 (DE3). Protein expression was induced at mid-log phase by adding 1 mM isopropyl b-D-1-thiogalactopyranoside for 4 h at 37 1C. Recombinant proteins were purified by affinity chromatography using standard methods 47 .
Glutathione-S-transferase pull-down assays and affinity chromatography. Affinity-purified GST fusion proteins were used for radioactively labeled pulldown assays as described previously 46 . Bound proteins were eluted by boiling in SDS sample buffer and analyzed by SDS-PAGE.
Co-immunoprecipitation and antibodies. Co-immunoprecipitation experiments were carried out following standard protocols 47 . Antibody to FGFR was purchased from Oncogene-EMD Biosciences, antibody to phospho-Tyr 4G10 was purchased from Upstate and antibody to CD8 was purchased from Caltag-Invitrogen. Antibodies corresponding to the MAPK pathways (p-c-raf, pERK1/2, phospho-p38 and p-SAPK/JNK) were purchased from Cell Signaling Technology. Antibody to HA-tag was purchased from Clontech.
Signal transduction analysis in PC12 cells. Rat pheochromocytoma PC12 cells were maintained in RPMI 1640 medium with L-glutamine supplemented with 10% heat-inactivated horse serum (vol/vol) and 5% fetal bovine serum (vol/ vol). For experiments, 1.5 Â 10 5 PC12 cells per well (coated with poly-D-lysine) were grown in supplemented medium for 48 h. The cells were washed once and serum starved in RPMI 1640 (0.25% horse serum/0.25% fetal bovine serum) for 48 h to prevent serum-activated phosphorylation. Cells were treated with ligands as described in the figure legends and lysed by removing the medium and adding 50 ml per well of 1Â sample buffer. The extracts were sonicated and samples were analyzed by SDS-PAGE and immunoblotting. Immunoblots were quantified using NIH Image 1.52. The data (at least four repeats for each experiment) are presented as means ± s.e.m. and statistical differences were determined by Student's t test.
PC12 cell differentiation. Sterile poly-D-lysine-coated cover slips were used to grow PC12 cells at a density of 2 Â 10 5 cells per 10 cm 2 . Plated cells were grown in 3 ml of nonsupplemented medium for 24 h. Ligands were added to the cells and incubated at 37 1C for 48 h, new ligands were added to fresh nonsupplemented medium and incubation was continued for 48 h at 37 1C. Cells were then fixed with 4% cold paraformaldehyde (wt/vol), the cover slips were mounted on slides and the cells were analyzed by light/phase-contrast microscopy.
Hippocampal neuronal cultures. Primary hippocampal cultures from embryonic day 18-19 Sprague-Dawley rats were transfected with CD8 as a cellmorphology marker 48 . Neurons were transfected at 6 d in vitro (DIV). At 11 DIV, neurons were starved for 3 h before performing the different treatments. All treatments were for 3 h and the neurons were fixed for immunocytochemistry.
Mammalian cellular expression. Transfection of COS-7 cells was performed using standard methods. Cells were grown to 60% confluence and then transfected with the indicated constructs with FuGENE according to the manufacturer's protocol (Roche Applied Science).
cAMP enzyme immunoassay. cAMP production from stimulated cells was quantified using a nonradioactive cAMP enzyme immunoassay kit following the manufacturer's protocol (Sigma).
Electrophysiology procedures. Individual slices were transferred to a submersion-style recording chamber and continuously superfused with artificial cerebrospinal fluid bubbled with 95% O 2 /5% CO 2 at a rate of 2-3 ml min -1 at 31-33 1C. Visualized, whole-cell voltage recordings were performed on striatal medium spiny neurons using infrared differential interference contrast video microscopy with an Olympus OLY-150 camera/controller system (Olympus). Recordings were obtained using a computer-controlled MultiClamp 700A amplifier (Molecular Devices). In all experiments, 10 mM (-) bicuculline methiodide was added to the superfusion medium to block GABA A receptor-mediated synaptic responses. Patch electrodes were created by pulling BF150-86-10 glass on a P-97 Flaming/Brown micropipette puller (Sutter Instrument) and were fire polished before use. Pipette resistance was typically 2-5 MO when filled with internal solution. The internal pipette solution contained 120 mM cesium methylsulfate, 5 mM NaCl, 10 mM TEA-Cl, 10 mM HEPES, 5 mM QX-314, 0.2 mM EGTA, 4 mM Mg 2 ATP, 0.3 mM Na 2 GTP, 10 mM phosphocreatine, pH 7.2 adjusted with CsOH, 280-290 mOsm L -1 . For evoked excitatory postsynaptic current (eEPSC) recordings, medium spiny neurons were voltage clamped at -70 mV. Test stimuli were delivered with an S48 stimulator (W. Warwick) and DS3 isolator (Digitimer) at a frequency of 0.05 or 0.1 Hz through a concentric electrode (Frederick Haer & Co). After a stable eEPSC baseline had been established (410 min), the cortex was stimulated at high frequency. The HFS protocol consisted of four 1-s episodes, during which the cortex was stimulated at 100 Hz; episodes were separated by 10-s intervals. During the HFS protocol, neurons were depolarized to 0 mV from a holding potential of -70 mV. Access resistance was monitored on-line, and if it changed by 420% during the course of recording, the cell was discarded. Synaptic responses were analyzed using pClamp. The traces shown in Figure 6 are averages of 10-15 individual sweeps in a given recording. In pre-incubation experiments, FGF and/or CGS21680 were added to the solution bathing the slices for at least 30 min before recording.
Chemicals and reagents. QX-314, (-)-quinpirole hydrochloride, CGS21680 hydrochloride, NBQX, ifenprodil, SCH58261 and SCH23390 hydrochloride
